Advances in human genetics, circuit biology, and translational biomarkers have expanded researchers’ ability to investigate the biology underlying psychiatric disorders.
2
Earlier target-engagement assessments and closer collaboration between discovery and clinical teams help evaluate mechanisms before programs advance.
3
EEG and brain imaging approaches, including receptor occupancy imaging and fMRI, are used or explored to assess target engagement and support dose selection.
4
Computational and multimodal methods may help researchers analyze heterogeneous data and identify psychiatric disease subgroups.
5
Fluid biomarkers, including inflammatory markers associated with an immunometabolic profile in some patients with depression, may help define subpopulations for study.
